Toinv, Buckeyes, RVXOldtimer, KK2 - Did we not hear at one point prior to the completion of BoM that there was a maximum number of patient that could be recruited in any one particular country? Memory is a little fuzzy but I think it was the AGM presentation the year prior to BoM wrapping up. There was a comment that Israel and 1 or 2 other countries reached their maximum number of recruits. Israel could have completely recruited the entire trial in short order but they had reached their cap, and there was an explanation of what that cap was.

With that in mind Hepa may only have an exposure of 20% of the entire trial. China, Hong Kong, Tiwan and Macau each being 10% of recruits and Hepa having a cap at 50% of expenditures in the China region. That 10% may actually be 12% X's 4 for a total of 48% divided by 2 now being a total of 24% of the total trial costs. One more wrench in the mix, Tiwan. Could this be causing some issues in this relationship? If there are any issues, is it coming from Hepa or being forced on them from national concerns?

RVX Oldtimer you are really good at finding this type of data. Somewhere I think you will find Hepa's total exposure is to be capped at up to 25% of total trial costs.

tada